Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sierra Oncology

Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
From Sierra Oncology
Via Business Wire
Tickers SRRA
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Reports First Quarter 2022 Results
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Tickers SRRA
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology to Participate in Guggenheim Oncology Conference
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Pricing of Upsized Public Offering of Securities
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Proposed Public Offering of Common Stock
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis
From Sierra Oncology
Via Business Wire
Tickers SRRA
Momelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis Patients
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Reports Baseline Ferritin Differentially Predicts Week 24 Transfusion Independence Response in Myelofibrosis Patients
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Investor Event to Review MOMENTUM Trial Design and Available Phase 3 Momelotinib Data in Myelofibrosis
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Presentation at Jefferies London Healthcare Conference
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Reports Third Quarter 2021 Results
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Momelotinib Poster Accepted for Presentation at ASH
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology to Present at Three September Investor Conferences
From Sierra Oncology
Via Business Wire
Tickers SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Tickers SRRA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.